<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">340944</article-id><article-id pub-id-type="doi">10.26442/00403660.2023.03.202073</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Possibilities of non-invasive diagnosis of fibrotic phenotype of interstitial lung diseases</article-title><trans-title-group xml:lang="ru"><trans-title>Возможности неинвазивной диагностики фибротического фенотипа интерстициальных заболеваний легких</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9146-0904</contrib-id><name-alternatives><name xml:lang="en"><surname>Shchepikhin</surname><given-names>Evgeniy I.</given-names></name><name xml:lang="ru"><surname>Щепихин</surname><given-names>Евгений Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач-пульмонолог, аспирант отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения</p></bio><email>shhepikhin11@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1908-5601</contrib-id><name-alternatives><name xml:lang="en"><surname>Shmelev</surname><given-names>Evgene I.</given-names></name><name xml:lang="ru"><surname>Шмелев</surname><given-names>Евгений Иванович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., гл. науч. сотр. отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения</p></bio><email>shhepikhin11@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2494-9275</contrib-id><name-alternatives><name xml:lang="en"><surname>Ergeshov</surname><given-names>Atadzhan E.</given-names></name><name xml:lang="ru"><surname>Эргешов</surname><given-names>Атаджан Эргешович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>чл.-кор. РАМН, д-р мед. наук, проф., дир.</p></bio><email>shhepikhin11@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7155-5730</contrib-id><name-alternatives><name xml:lang="en"><surname>Zaytseva</surname><given-names>Anna S.</given-names></name><name xml:lang="ru"><surname>Зайцева</surname><given-names>Анна Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, ст. науч. сотр. отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения</p></bio><email>shhepikhin11@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1433-5720</contrib-id><name-alternatives><name xml:lang="en"><surname>Shergina</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Шергина</surname><given-names>Елена Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. мед. наук, зав. отд-нием функциональной диагностики</p></bio><email>shhepikhin11@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0937-3167</contrib-id><name-alternatives><name xml:lang="en"><surname>Adamovskaya</surname><given-names>Evgeniy  N.</given-names></name><name xml:lang="ru"><surname>Адамовская</surname><given-names>Евгения Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>врач-пульмонолог, аспирант отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения</p></bio><email>shhepikhin11@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Central Tuberculosis Research Institute</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Центральный научно-исследовательский институт туберкулеза»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-04-26" publication-format="electronic"><day>26</day><month>04</month><year>2023</year></pub-date><volume>95</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>230</fpage><lpage>235</lpage><history><date date-type="received" iso-8601-date="2023-04-24"><day>24</day><month>04</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-04-24"><day>24</day><month>04</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/340944">https://ter-arkhiv.ru/0040-3660/article/view/340944</self-uri><abstract xml:lang="en"><p>Progressive pulmonary fibrosis is a major problem in respiratory medicine. Currently, there are no reliable biomarkers for early diagnosis of progressive pulmonary fibrosis, which leads to delayed diagnosis.</p> <p><bold>Aim.</bold> To determine the role of serum biomarkers CA-19-9 and CA-125 and the possibilities of capillaroscopy of the nail fold in the diagnosis of progressive pulmonary fibrosis.</p> <p><bold>Materials and methods. </bold>The study included 43 patients with interstitial changes in the lungs. Based on the presence/absence of signs of progression over the previous 12 months, patients were divided into 2 groups. All patients underwent forced spirometry, body plethysmography, diffusion test, CT, lung ultrasound, capillaroscopy of the nail fold, study of serum concentrations of CA-19-9 and CA-125.</p> <p><bold>Results.</bold> In the group of patients with a progressive fibrotic phenotype of Interstitial lung diseases, a greater severity of capillaroscopic changes and a higher level of CA-19-9 were revealed. Correlation of these parameters with changes according to CT scan data (Warrick test) and lung ultrasound was shown.</p> <p><bold>Conclusion. </bold>The data obtained demonstrate the possibilities of non-invasive diagnosis of progressive fibrosing interstitial lung diseases and require further research and prospective follow-up to assess the diagnostic and prognostic role of the studied biomarkers, as well as to determine their place in clinical practice.</p></abstract><trans-abstract xml:lang="ru"><p>Прогрессирующий фиброз (ПФ) легких – важнейшая проблема в респираторной медицине. В настоящее время надежные биомаркеры для ранней диагностики ПФ легких отсутствуют, что приводит к несвоевременной диагностике.</p> <p><bold>Цель работы. </bold>Определить роль сывороточных биомаркеров СА-19-9 и СА-125 и возможности капилляроскопии ногтевого валика в диагностике прогрессирующего легочного фиброза.</p> <p><bold>Материалы и методы. </bold>В исследование включены 43 пациента с интерстициальными изменениями в легких. На основании наличия/отсутствия признаков прогрессирования за предшествующие 12 мес пациенты разделены на 2 группы. Всем пациентам выполнялись форсированная спирометрия, бодиплетизмография, диффузионный тест, компьютерная томография органов грудной клетки, ультразвуковое исследование легких, капилляроскопия ногтевого валика, исследование сывороточной концентрации СА-19-9 и СА-125.</p> <p><bold>Результаты. </bold>В группе пациентов с прогрессирующим фибротическим фенотипом интерстициальных заболеваний легких (ИЗЛ) выявлены большая выраженность капилляроскопических изменений и более высокий уровень СА-19-9. Показана корреляция этих параметров с изменениями по данным компьютерной томографии органов грудной клетки (Warrick-тест) и ультразвукового исследования легких.</p> <p><bold>Заключение.</bold> Полученные данные демонстрируют возможности неинвазивной диагностики ПФ-ИЗЛ и требуют дальнейших исследований и проспективного наблюдения для оценки диагностической и прогностической роли исследуемых биомаркеров, а также определения их места в клинической практике.</p></trans-abstract><kwd-group xml:lang="en"><kwd>interstitial lung disease</kwd><kwd>pulmonary fibrosis</kwd><kwd>microcirculation</kwd><kwd>COVID-19</kwd><kwd>oncomarkers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>интерстициальные заболевания легких</kwd><kwd>легочный фиброз</kwd><kwd>микроциркуляция</kwd><kwd>COVID-19</kwd><kwd>онкомаркеры</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med. 2020;383(10):958-68. DOI:10.1056/NEJMra2005230</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Wild JM, Porter JC, Molyneaux PL, et al. Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). BMJ Open Respir Res. 2021;8(1):e001049. DOI:10.1136/bmjresp-2021-001049</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before and after COVID-19: a double threat? Eur Respir J. 2021;58(6):2101956. DOI:10.1183/13993003.01956-2021</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hilberg O, Hoffmann-Vold AM, Smith V, et al. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Res. 2022;8(1):00597-2021. DOI:10.1183/23120541.00597-2021</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Gagliardi M, Berg DV, Heylen CE, et al. Real-life prevalence of progressive fibrosing interstitial lung diseases. Sci Rep. 2021;11(1):23988. DOI:10.1038/s41598-021-03481-8</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Dhooria S, Sehgal IS, Agarwal R, et al. Incidence, prevalence, and national burden of interstitial lung diseases in India: Estimates from two studies of 3089 subjects. PLoS One. 2022;17(7):e0271665. DOI:10.1371/journal.pone.0271665</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hoffmann-Vold AM, Allanore Y, Alves M, et al; EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219-27. DOI:10.1136/annrheumdis-2020-217455</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Lorent N, Vande Weygaerde Y, Claeys E, et al. Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge. ERJ Open Res. 2022;8(2):00004-2022. DOI:10.1183/23120541.00004-2022</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>John AE, Joseph C, Jenkins G, Tatler AL. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021;302(1):228-40. DOI:10.1111/imr.12977</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021;38(Suppl.):S41-7. DOI:10.4103/lungindia.lungindia_818_20</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Allen RJ, Guillen-Guio B, Croot E, et al. Genetic overlap between idiopathic pulmonary fibrosis and COVID-19. Eur Respir J. 2022;60(1):2103132. DOI:10.1183/13993003.03132-2021</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Dhooria S, Maturu VN, Talwar D, et al. A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities. Lung India. 2022;39(3):254-60. DOI:10.4103/lungindia.lungindia_568_21</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Al-Kuraishy HM, Batiha GE, Faidah H, et al. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology. 2022;30(6):2017-26. DOI:10.1007/s10787-022-01027-6</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47. DOI:10.1164/rccm.202202-0399ST</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zhong D, Wu C, Bai J, et al. Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis. Medicine (Baltimore). 2020;99(16):e19695. DOI:10.1097/MD.0000000000019695</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Elhai M, Avouac J, Allanore Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand? Semin Arthritis Rheum. 2020;50(3):480-91. DOI:10.1016/j.semarthrit.2020.01.006</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Barratt SL, Creamer AW, Adamali HI, et al. Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study. BMJ Open Respir Res. 2021;8(1):e001063. DOI:10.1136/bmjresp-2021-001063</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Achaiah A, Rathnapala A, Pereira A, et al. Monocyte and neutrophil levels are potentially linked to progression to IPF for patients with indeterminate UIP CT pattern. BMJ Open Respir Res. 2021;8(1):e000899. DOI:10.1136/bmjresp-2021-000899</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Tomassetti S, Poletti V, Ravaglia C, et al. Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives. Eur Respir Rev. 2022;31(164):210206. DOI:10.1183/16000617.0206-2021</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Trappe A, Donnelly SC, McNally P, Coppinger JA. Role of extracellular vesicles in chronic lung disease. Thorax. 2021;76(10):1047-56. DOI:10.1136/thoraxjnl-2020-216370</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017;5(12):946-55. DOI:10.1016/S2213-2600(17)30430-7</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Yanagihara T, Jones KD. Demystifying morphomolecular alterations of vasculature in interstitial lung diseases. Eur Respir J. 2020;55(3):1902446. DOI:10.1183/13993003.02446-2019</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Ackermann M, Stark H, Neubert L, et al. Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases. Eur Respir J. 2020;55(3):1900933. DOI:10.1183/13993003.00933-2019</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Chung JH, Adegunsoye A, Cannon B, et al. Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. J Clin Med. 2021;10(12):2663. DOI:10.3390/jcm10122663</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Smith V, Thevissen K, Trombetta AC, et al; EULAR Study Group on Microcirculation in Rheumatic Diseases. Nailfold Capillaroscopy and Clinical Applications in Systemic Sclerosis. Microcirculation. 2016;23(5):364-72. DOI:10.1111/micc.12281</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ruaro B, Confalonieri M, Salton F, et al. The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients. Pharmaceuticals (Basel). 2021;14(5):403. DOI:10.3390/ph14050403</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Buda N, Piskunowicz M, Porzezińska M, et al. Lung Ultrasonography in the Evaluation of Interstitial Lung Disease in Systemic Connective Tissue Diseases: Criteria and Severity of Pulmonary Fibrosis – Analysis of 52 Patients. Ultraschall Med. 2016;37(4):379-85. DOI:10.1055/s-0041-110590</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Shumar JN, Chandel A, King CS. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. J Clin Med. 2021;10(11):2285. DOI:10.3390/jcm10112285</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Mori Y, Kondoh Y. What parameters can be used to identify early idiopathic pulmonary fibrosis? Respir Investig. 2021;59(1):53-65. DOI:10.1016/j.resinv.2020.10.008</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Sugino K, Ono H, Watanabe N, et al. Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis. BMC Pulm Med. 2021;21(1):218. DOI:10.1186/s12890-021-01595-3</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18(10):1520-8</mixed-citation></ref></ref-list></back></article>
